Slide 1: Financial Results Nine Months of 2025
FINANCIAL RESULTS NINE MONTHS OF 2025
Slide 2: Statement
STATEMENT This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presentati
Slide 3: Contents
CONTENTS → 9M 2025 results → Results statement and balance sheet for 9M 2025 → RJF stock performance 3
Slide 4: 9M 2025 in brief
1S 2025 9M 2025EN IN BREVE BRIEF • The €25 million EMINTECH project (2023-2026) is dedicated to tackling antimicrobial resistance (AMR) EMINTECH - IPCEI and rare diseases through the development of advanced pharmaceutical technologies. Project • €13 million grant awarded by the Centre for Technologi
Slide 5: 9M 2025 Results
First signs of recovery despite the burden of the 9M 2025 RESULTS antibiotics business Sed ut perspiciatis • The sales number for the first nine months of the year decreased by –4% compared to the same SALES period in 2024 due to a temporary lower production of antibiotics at Pharmaceutical Technolo
Slide 6: EBITDA 9M 2025
Excluding extraordinary impacts, pro forma EBITDA 9M 2025 recurring EBITDA increased by 2%. millions of euros 9M 2025 +2% 24 7 -1 3 33 Temporary reduction Reducción Capacidad Otros Other Proyectos Projects Reported EBITDA EBITDA Reportado in production productiva temporal EMINTECH Proyecto project E
Slide 7: Flash Results 9M 2025 vs 9M 2024
FLASH RESULTS 9M 2025 VS 9M 2024 SALES EBITDA PRO FORMA EBITDA € 242 M € 24,0 M € 33,0 M -4% -17% +2% CDMO € 41 M /-18% NET RESULT INNOVACIÓN OPERATINGEN NFD/EBITDA CASH RJF continues to INNOVACIÓN EN advance its transition INNOVACIÓN EN € 1,9 MY MARCA PRODUCTO 2,1 XTECNOLOGÍA FLOW INDUSTRIAL and op
Slide 8: 9M 2025 Revenues by Business Unit
9M 2025 REVENUES BY BUSINESS UNIT millions of euros SALES 9M25 242 M€ -4% PHARMACEUTICAL 40% SPECIALTY 36% CONSUMER 24% TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC 98M€ / -12% 86 M€ / +1% 58 M€ / +3% Antibiotics € 35 M Dermatology € 27 M ENT RJ € 11 M (33 %) +18 % (0 %) Injectables Forté Pharma f
Slide 9: 9M 2025 Revenues by Business Unit
9M 2025 REVENUES BY BUSINESS UNIT millions of euros SALES 9M25 242 M€ -4% PHARMACEUTICAL 40% SPECIALTY 36% CONSUMER 24% TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC 98M€ / -12% 86 M€ / +1% 58 M€ / +3% • Antibiotic sales have dropped by 33% due to a • Dermatology grew by +18%, led by sales of • Sal
Slide 10: International Presence and Sales
INTERNATIONAL TOTAL PRESENCE Sed ut perspiciatis SALES Q3 2025 Spain Rest of Sed ut perspiciatis Europe Rest of the world SALES GROWTH Q3 2025 +70 COUNTRIES € 242 M 102 M€ 115 M€ 42% 47% 25 M€ 11% -4% -4% -10% Rest of Europe Asia 7% 47% Rest of the world 4% RJF maintains its focus on global expansio
Slide 11: Income Statement
INCOME STATEMENT • Sales figures fell by 4%, with an associated gross margin of 61%, 1.4 points higher than in the same period last year due to a better mix of more productive sales. INCOME STATEMENT (thousand euros) 30/09/2025 30/09/2024 V% • Other operating income includes the grant received in co
Slide 12: Balance Sheet: Assets and Investments
BALANCE SHEET INVESTMENTS Q3 2025 ASSETS AND INVESTMENTS Millones de Euros BALANCE SHEET (thousand euros) 30/09/2025 31/12/2024 Goodwill 27.005 26.809 INDUSTRIAL Other intangible assets 51.225 55.285 CAPEX Property, plant and equipment 101.423 97.030 15.0 Investments in equity-accounted investees 10
Slide 13: Balance Sheet: Liabilities and Debts
BALANCE SHEET GROSS FINANCIAL DEBT LIABILITIES AND DEBTS 9.9 BALANCE SHEET (thousand euros) 30/09/2025 31/12/2024 78.5 DEBT LEASES APPLICATION IFRS 16 Millions of € TOTAL EQUITY 216.971 213.950 Millions of € DEBT WITH CREDIT INSTITUTIONS + 68.7 Capital grants 5.750 3.620 OTHER PUBLIC BODIES Millions
Slide 14: Evolution of Market Capitalisation
EVOLUTION OF MARKET CAPITALISATION €230M RJF YTD SHARES YTD SEP 25 VOLUME CASH RJF (ISIN ES0165359029) €2,80/Share - 30/09/2025 VALUATION maximum minimum 5.2 M €15.0 M €2.86 /Share €3.31/Share €2.48/Share YTD Titles YTD SHAREHOLDER COMPOSITION Weighted average 10/06/2025 16/01/2025 27K titles €79K Y
Slide 15: Alternative Performance Measures
ALTERNATIVE PERFORMANCE MEASURES Management uses certain alternative performance measures in making financial, operating and planning decisions, as well as to evaluate the performance of the Group and its subsidiaries. Management believes that these alternative performance measures provide additiona
Slide 16: Links and Complementary Information
LINKS AND INFORMATION → RESULTS WEBCAST COMPLEMENTARY https://reigjofre.com/es/inversores/webcasts/ https://reigjofre.com/es/inversores/presentaciones/ → SUBSCRIPTION CENTRE http://www.reigjofre.com/es/noticias/centro-suscripcion → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre
Slide 17: Thank You
THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN www.reigjofre.com Investor Relations investors@reigjofre.com